A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Promoteur : Janssen Research & Development, LLC
Titre et résumé fournis en anglais par le registre source, reproduits sans traduction ni interprétation.
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \[RP2D\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).
Vous quittez essai-clinique.com pour le site externe clinicaltrials.gov, géré par l’organisme responsable de l’annonce. La candidature, les questions d’éligibilité et toute information médicale se traitent uniquement là-bas.
Important
essai-clinique.com ne recueille pas de candidature et ne détermine pas votre éligibilité. Ne transmettez aucune information médicale au site.
Les critères affichés sont une synthèse des informations disponibles. Seul l’organisme responsable de l’étude peut confirmer l’éligibilité d’une personne.